[Factors predictive of chemotherapy resistance in patients with breast cancer].
作者信息
Dumontet C
机构信息
INSERM U 453, Lyon.
出版信息
Ann Pathol. 2000;20 Suppl:S94.
PMID:11261312
Abstract
摘要
相似文献
1
[Factors predictive of chemotherapy resistance in patients with breast cancer].[乳腺癌患者化疗耐药的预测因素]
Ann Pathol. 2000;20 Suppl:S94.
2
[High dose chemotherapy in ovarian and breast adenocarcinoma with poor prognosis].[高剂量化疗用于预后不良的卵巢和乳腺腺癌]
Gynecol Obstet Fertil. 2000 Sep;28(9):620-31.
3
Prophylactic chemotherapy following breast cancer: a personal experience.乳腺癌后的预防性化疗：个人经历
Nurs Times. 1977 Jul 7;73(27):1050-1.
4
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.伊沙匹隆作为乳腺癌新辅助治疗的II期基因组学研究。
J Clin Oncol. 2009 Feb 1;27(4):526-34. doi: 10.1200/JCO.2007.14.2646. Epub 2008 Dec 15.
5
Introduction: chemotherapies in the treatment of breast cancer.引言：乳腺癌治疗中的化疗
Semin Oncol. 2005 Dec;32(6 Suppl 7):S1-2. doi: 10.1053/j.seminoncol.2005.09.012.
6
Drug resistance in chemotherapy for breast cancer.乳腺癌化疗中的耐药性。
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:84-9. doi: 10.1007/s00280-005-0106-4.
7
Advances in chemotherapy options for metastatic breast cancer: introduction of epothilones.转移性乳腺癌化疗方案的进展：埃坡霉素的引入。
ONS Connect. 2007;22(8 Suppl):29-30.
8
Ixabepilone (Ixempra) for breast cancer.伊沙匹隆（Ixempra）用于治疗乳腺癌。
Med Lett Drugs Ther. 2008 Jan 28;50(1278):7-8.
9
Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.螺锗治疗乳腺腺癌的II期试验：一项癌症与白血病B组研究
Cancer Treat Rep. 1982 Aug;66(8):1667-8.
10
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.通过醛脱氢酶1表达鉴定的乳腺癌干细胞与乳腺癌序贯紫杉醇和表柔比星化疗耐药性的关联。
Clin Cancer Res. 2009 Jun 15;15(12):4234-41. doi: 10.1158/1078-0432.CCR-08-1479. Epub 2009 Jun 9.
Zotero 插件